Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) CAO Theodore Alan Huizenga sold 132 shares of the business’s stock in a transaction dated Saturday, April 16th. The stock was sold at an average price of $84.55, for a total transaction of $11,160.60. Following the completion of the sale, the chief accounting officer now directly owns 16,914 shares of the company’s stock, valued at approximately $1,430,078.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
RARE stock traded up $1.17 on Tuesday, hitting $79.61. 3,980 shares of the company’s stock traded hands, compared to its average volume of 437,963. Ultragenyx Pharmaceutical Inc. has a 1-year low of $61.21 and a 1-year high of $119.54. The firm has a market cap of $5.52 billion, a PE ratio of -11.69 and a beta of 1.68. The stock’s fifty day moving average is $71.42.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its quarterly earnings results on Thursday, February 10th. The biopharmaceutical company reported ($1.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.47). The firm had revenue of $83.39 million during the quarter, compared to analysts’ expectations of $83.68 million. Ultragenyx Pharmaceutical had a negative net margin of 129.20% and a negative return on equity of 44.24%. The firm’s revenue was down 8.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.34) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.57 earnings per share for the current fiscal year.
RARE has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 31st. They set a “hold” rating for the company. JPMorgan Chase & Co. upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 target price for the company in a research report on Friday, February 11th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 target price for the company in a research report on Tuesday, February 15th. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, February 11th. Finally, Credit Suisse Group upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $99.00 to $105.00 in a research report on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $122.27.
Ultragenyx Pharmaceutical Company Profile (Get Rating)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.